FDA #OrphanDrug status granted to Santen Sirolimus drug

In Uncategorized by Caroline Hornby

santen awarded orphan drug status by fda The US FDA has granted orphan drug status for Santen’s sirolimus (DE-109, rapamycin) to treat chronic/refractory anterior non-infectious uveitis, non-infectious intermediate uveitis, non-infectious panuveitis, and non-infectious uveitis affecting the posterior segment of the eye.

The status has been granted by FDA following the approval of orphan drug status by the European Commission in September 2011.

Read the full article here.

For more information on orphan drugs and rare diseases, check out the World Orphan Drug Congress USA.